Small bowel permeability in patients with cytostatic therapy
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
10422084
DOI
10.1016/s0899-9007(99)00113-6
PII: S0899900799001136
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Epirubicin adverse effects MeSH
- Fluorouracil adverse effects MeSH
- Gastrointestinal Neoplasms drug therapy physiopathology MeSH
- Intestinal Absorption drug effects MeSH
- Lactulose pharmacokinetics MeSH
- Leucovorin adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Mannitol pharmacokinetics MeSH
- Mitomycins adverse effects MeSH
- Permeability MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Intestine, Small drug effects injuries physiopathology MeSH
- Xylose pharmacokinetics MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Epirubicin MeSH
- Fluorouracil MeSH
- Lactulose MeSH
- Leucovorin MeSH
- Mannitol MeSH
- Mitomycins MeSH
- Xylose MeSH
The purpose of this study was to examine the influence of cytostatic therapy on the barrier function of the small bowel. In 16 patients with tumors in the gastrointestinal tract with metastatic involvement of the liver, small bowel permeability was measured using the lactulose/mannitol test. The patients were treated for 5 d with fluorouracil (750-1000 mg/d) and leucovorin (25-50 mg/d). The examination was performed on the first day, at the beginning of the cytostatic therapy, and also 5, 12, and 28 d after the therapy had begun. In comparing the start and the end of this therapy, the index of permeability was significantly increased (as measured 7 d after the end of therapy). These results show the damage of small bowel barrier after cytostatic therapy.
References provided by Crossref.org
